Skip to content
HowShorted

BioXcel Therapeutics, Inc. short interest in 2021

In 2021, BioXcel Therapeutics, Inc.'s disclosed short interest ran from 15.07% of shares outstanding on 15 Jan 2021 to 6.18% on 31 Dec 2021, a change of -8.89 percentage points. The year's high was 15.09% on 15 Mar 2021 and its low 6.18% on 31 Dec 2021, averaging 10.56% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 17.82 days on 28 May 2021. Full history: BioXcel Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for BioXcel Therapeutics, Inc. in 2021

2021 in figures

Start of year
15.07% (15 Jan 2021)
End of year
6.18% (31 Dec 2021)
Change
-8.89 pp
High
15.09% (15 Mar 2021)
Low
6.18% (31 Dec 2021)
Average
10.56%
Highest days to cover
17.82 (28 May 2021)

Every report in 2021

BioXcel Therapeutics, Inc. short interest in 2021
SettlementShort interestDays to coverFilings since previous
15 Jan 202115.07%5.09
29 Jan 202113.86%7.00
12 Feb 202114.65%6.35
26 Feb 202114.81%8.61
15 Mar 202115.09%8.17
31 Mar 202113.65%6.88
15 Apr 202114.86%6.20
30 Apr 202113.71%11.91
14 May 202112.92%9.53
28 May 202112.52%17.82
15 Jun 202111.83%11.60
30 Jun 202112.10%4.03
15 Jul 202110.65%6.00
30 Jul 20219.59%6.91
13 Aug 20217.95%8.88
31 Aug 20217.31%7.65
15 Sep 20216.79%8.13
30 Sep 20216.59%7.15
15 Oct 20216.19%6.02
29 Oct 20216.69%9.63
15 Nov 20216.40%5.53
30 Nov 20217.09%5.83
15 Dec 20217.00%5.34
31 Dec 20216.18%6.04

See also: BioXcel Therapeutics, Inc.'s full history · most shorted US stocks of 2021 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.